Please login to the form below
The Competition and Markets Authority
This page shows the latest The Competition and Markets Authority news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance
The EU clearance comes after similar competition clearances in the US, Japan and other global regulatory agencies, AZ said in a statement. ... In May, the UK’s Competition and Markets Authority (CMA) announced that it was reviewing AZ’s proposed
Latest news
-
UK’s Competition and Markets Authority to review AZ/Alexion merger
The UK’s Competition and Markets Authority (CMA) is set to review AstraZeneca’s (AZ) planned takeover of rare diseases specialist Alexion. ... Competition clearances have also been completed in Canada, Brazil, Russia and other countries.
-
Roche to close $4.3bn Spark deal after FTC clearance
The US antitrust approval swiftly follows the clearance from the UK’s Competition and Markets Authority (CMA), which announced early yesterday that its investigation into the merger was complete. ... However, the antitrust authority finally concluded
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
the UK's Competition and Markets Authority (CMA) finally approved the deal. ... The CMA therefore found that the deal between Roche and Spark would not negatively affect competition because UK health services and patients will still have an adequate
-
Pfizer, Flynn face reinstatement of £90m CMA fine
Facing penalty for dramatic price hikes of an epilepsy drug. The UK’s competition regulator is pushing to reinstate a £90m fine for Pfizer and Flynn Pharma – quashed last year – over ... The case dates back to 2015, when the Competition and
-
Roche moving closer to approval of Spark takeover; report
Competition and Markets Authority (CMA) have taken their time to probe antitrust issued raised by the deal. ... The Capitol Forum report suggests that review staff are happy to accept the deal, but that senior officials at the FTC's Bureau of
More from news
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs. The Competition and Markets Authority (CMA) is tasked with strengthening business competition and reducing anti-competitive practices for the benefit of ... were hampering healthy competition. The
-
Vertex: a vision of treating all CF patients worldwide draws closer
The analysts also now predict Vertex will be able to maintain its prices in both markets, rather than have to drop them slightly in the face of competition. ... could refer the company to the Competition and Markets Authority for “what appears to us to
-
A healthcare landscape going through seismic change
Nordkamp took time out from judging the entries to stress the importance of technological disruption to the UK and global markets. ... The company is still reeling from its record £84.2m fine last December from the UK government’s Competition and
More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
